ArticleBMC infectious diseases2026
Viral load suppression among pregnant and breastfeeding women living with HIV in Ghana: a prospective longitudinal study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimising Post-Delivery Viral Load Monitoring and HIV Care to Eliminate Breastfeeding-Associated HIV Transmission in Sub-Saharan Africa: A Review.Tropical medicine and infectious disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe post-delivery period is a critical window for sustaining maternal viral suppression (VS) to prevent vertical transmission (VT) of HIV during breastfeeding. Despite Ghana’s national scale-up of dolutegravir-based antiretroviral therapy, limited data exist on viral load suppression and infant HIV outcomes in the year post-delivery. We aimed to determine the proportion of women who achieved and maintained a suppressed viral load (VL) (≤ 1000 copies/mL) and an undetectable VL (< 20 copies/mL) at 12 months post-delivery and examine associations between maternal characteristics and VL categories.
methodsWe conducted a prospective longitudinal cohort study among 120 women living with HIV receiving ART across two tertiary hospitals in Ghana. Women were enrolled during late pregnancy or early post-delivery and followed up at 6 weeks and 3-, 6-, and 12-months post-delivery, during which maternal VL was monitored. Infant HIV status was documented at 6 weeks and 9 months in accordance with national guidelines. Our co-primary outcomes were VL suppression and undetectable VL at 12 months.
resultsThe median maternal age was 31.0 years (28.0, 36.3), and nearly half of the participants had attained only primary-level education (58/120; 46.7%). At 12 months post-delivery, 65 participants (54.2%) had documented VS, and out of this, 41 (34.2%) had an undetectable VL. Two cases of VT of HIV were documented: one at 6 weeks (maternal VL 669 copies/mL) and another at 6 months (maternal VL 64 copies/mL), underscoring the transmission risk even with low-level viremia. VL data were missing among 49 participants (40.8%) despite follow-up efforts. Women on the tenofovir/lamivudine/dolutegravir regimen were more likely to achieve suppression than were those on the regimen without an integrase inhibitor, p = 0.04.
conclusionsJust over half of women achieved VS at 12 months post-delivery. VT occurred even at low levels of maternal viremia, underscoring the importance of sustained VL monitoring and optimisation of antiretroviral therapy during the post-delivery period. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.